Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 19, 2021 | May 22, 2021 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 04, 2026 | February 06, 2026 |
| Urovant Sciences Ltd.UROV · Entity 140739 | Director · PEO;CEO/Urovant Sciences, Inc. | February 19, 2020 | February 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,575 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 8,575 · Balance 8,575 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 8,575 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,294 |
Ending reported balance
After 2026-04-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 111,775 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Row 2 · 2026-04-30 · Sale · Disposed 15,481 · Balance 96,294 F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F4: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F5: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F5: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
RIGEL PHARMACEUTICALS INC
Report date May 19, 2021 · Filed May 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-05-19 transaction · row 1
1 source rowRow 1 · 2021-05-19 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2031-05-19 | Direct | 30,000 |
Reported balance
After 2021-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-19 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors.
F2: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.
Syndax Pharmaceuticals Inc
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,000 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 124,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Urovant Sciences Ltd.
Report date February 19, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 199,680 |
Ending reported balance
After 2020-02-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-02-19 · Exercise / conversion · Acquired 180,000 · Balance 379,680 Row 2 · 2020-02-19 · Tax withholding · Disposed 104,788 · Balance 274,892 F1: Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options. Row 3 · 2020-02-19 · Other · Disposed 75,212 · Balance 199,680 F2: Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.86 · Expires 2027-09-21 | Direct | 701,254 |
Reported balance
After 2020-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-19 · Exercise / conversion · Acquired 180,000 · Balance 701,254 F3: All of the shares underlying this option are vested and exercisable as of the date hereof. F4: Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options.
F2: Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction.
F3: All of the shares underlying this option are vested and exercisable as of the date hereof.
F4: Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Options (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · derivative · entry 3 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F4 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F5 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,481 | $8.28 | $128,182.68 |
DisclosureSEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · nonDerivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,294 F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,775 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041192 · ownership.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionRestricted Stock Units · Derivative | 8,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015486 · ownership.xml · derivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionCommon Stock | 8,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015486 · ownership.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,844 | $6.30 | $49,417.20 |
DisclosureSEC source: 0001367644-25-000136 · wk-form4_1748462897.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,431 F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025. F2 · price: For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $6.22 - $6.35. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document |
| May 19, 2025 Filed May 19, 2025 20:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 10,000 | $9.11 | $91,120.00 |
DisclosureSEC source: 0000950170-25-074289 · ownership.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000106 · wk-form4_1746232243.xml · derivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000106 · wk-form4_1746232243.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,275 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016363 · ownership.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 8,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004922 · ownership.xml · derivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,575 Underlying: Common Stock · 8,575 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on January 10, 2026. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 77,175 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004922 · ownership.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,175 Underlying: Common Stock · 77,175 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 77,175 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000089 · wk-form4_1716946880.xml · derivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000089 · wk-form4_1716946880.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,872 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001218 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| May 25, 2023 Filed May 30, 2023 23:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000105 · wk-form4_1685487901.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,442 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:45 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 752,185 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026728 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,185 Underlying: Common Stock · 752,185 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 752,185 shares of Common Stock, which option vests with respect to 376,093 shares on May 1, 2024 and with respect to 376,092 shares on May 1, 2025. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:52 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000943 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:04 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006339 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 20,782 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · derivative · entry 6 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,782 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 9,117 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · derivative · entry 5 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,117 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 9,117 | $25.90 | $236,138.51 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · nonDerivative · entry 4 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.0000 to $26.4600. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 9,117 | $8.93 | $81,414.81 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · nonDerivative · entry 3 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 20,782 | $25.90 | $538,272.50 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · nonDerivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.0000 to $26.4600. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 20,782 | $7.88 | $163,762.16 |
DisclosureSEC source: 0001562180-22-007125 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 137 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 18 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 137 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 223 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 17 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 223 | $25.00 | $5,575.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 12 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale price was $25.00. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 223 | $8.93 | $1,991.39 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 11 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 137 | $25.00 | $3,425.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 10 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale price was $25.00. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 137 | $7.88 | $1,079.56 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 9 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 167 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 16 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 13 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 15 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 13 | $25.00 | $325.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 8 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale price was $25.00. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 13 | $8.93 | $116.09 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 7 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 167 | $25.00 | $4,175.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 6 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale price was $25.00. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 167 | $7.88 | $1,315.96 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 5 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,914 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 14 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,914 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 647 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · derivative · entry 13 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 647 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 647 | $25.07 | $16,220.74 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 4 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.00 to $25.215. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 647 | $8.93 | $5,777.71 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 3 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 2,914 | $25.07 | $73,056.02 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.00 to $25.215. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 2,914 | $7.88 | $22,962.32 |
DisclosureSEC source: 0001562180-22-007011 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2022 Filed Apr 5, 2022 20:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000061 · wf-form4_164919014507684.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,595 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:30 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001074 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006466 · doc4.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:57 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005767 · edgar.xml · derivative · entry 2 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:57 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005767 · edgar.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000927 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.